Hepatic lipid and glucose metabolism have been shown to be under tight circadian control in pre-clinical models. However, it remains unknown whether diurnal patterns exist in functional processes governing intrahepatic lipid accumulation in humans. We performed metabolic phenotyping, including state-of-the-art stable isotope techniques, during day and night in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and overweight controls (NCT05962099). The primary outcome was diurnal change in hepatic de novo lipogenesis (DNL), alongside a number of secondary outcomes, including changes in hepatic glucose production, glucose disposal, plasma non-esterified fatty acids (NEFAs), and whole-body glucose and lipid oxidation. We show that nighttime metabolic dysfunction is a hallmark of MASLD with multiple pathogenic pathways upregulated at night, including hepatic and peripheral insulin resistance, DNL, and systemic NEFA exposure. Insulin resistance is compounded by lower plasma insulin levels at night, secondary to reduced insulin secretion and elevated insulin clearance. Diurnal differences persist when performing identical investigations after weight loss with liver fat reductions, suggesting that nighttime metabolic dysfunction may be a primary driver of steatosis. These findings will help establish the optimal window for energy intake, exercise, and medication delivery in patients with MASLD. Integrated proteomics of plasma, adipose, and skeletal muscle tissue across day and night also identified a number of specific molecular targets that may offer therapeutic potential in the treatment of metabolic disease.

Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night / Marjot, T., Smith, K., Westcott, F., White, S., Johnson, E., Srnic, N., Barrett, A., Hall, E., Gralton, K., Dennis, K., Miller, H., Pofi, R., Cobbold, J.F.L., Richmond, R., Karpe, F., Blazev, R., Watt, M.J., Parker, B.L., Hodson, L., Ray, D.W., et al.. - In: CELL METABOLISM. - ISSN 1932-7420. - 38:3(2026), pp. 474-492. [10.1016/j.cmet.2025.12.004]

Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night

Pofi, Riccardo;
2026

Abstract

Hepatic lipid and glucose metabolism have been shown to be under tight circadian control in pre-clinical models. However, it remains unknown whether diurnal patterns exist in functional processes governing intrahepatic lipid accumulation in humans. We performed metabolic phenotyping, including state-of-the-art stable isotope techniques, during day and night in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and overweight controls (NCT05962099). The primary outcome was diurnal change in hepatic de novo lipogenesis (DNL), alongside a number of secondary outcomes, including changes in hepatic glucose production, glucose disposal, plasma non-esterified fatty acids (NEFAs), and whole-body glucose and lipid oxidation. We show that nighttime metabolic dysfunction is a hallmark of MASLD with multiple pathogenic pathways upregulated at night, including hepatic and peripheral insulin resistance, DNL, and systemic NEFA exposure. Insulin resistance is compounded by lower plasma insulin levels at night, secondary to reduced insulin secretion and elevated insulin clearance. Diurnal differences persist when performing identical investigations after weight loss with liver fat reductions, suggesting that nighttime metabolic dysfunction may be a primary driver of steatosis. These findings will help establish the optimal window for energy intake, exercise, and medication delivery in patients with MASLD. Integrated proteomics of plasma, adipose, and skeletal muscle tissue across day and night also identified a number of specific molecular targets that may offer therapeutic potential in the treatment of metabolic disease.
2026
adipose tissue; beta-oxidation; circadian; endogenous glucose production; GDF-15; glucose disposal; insulin clearance; insulin resistance; insulin secretion; lipid metabolism; skeletal muscle
01 Pubblicazione su rivista::01a Articolo in rivista
Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night / Marjot, T., Smith, K., Westcott, F., White, S., Johnson, E., Srnic, N., Barrett, A., Hall, E., Gralton, K., Dennis, K., Miller, H., Pofi, R., Cobbold, J.F.L., Richmond, R., Karpe, F., Blazev, R., Watt, M.J., Parker, B.L., Hodson, L., Ray, D.W., et al.. - In: CELL METABOLISM. - ISSN 1932-7420. - 38:3(2026), pp. 474-492. [10.1016/j.cmet.2025.12.004]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1776786
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 26
social impact